Choice of Cost-Effectiveness Measure in the Economic Evaluation of Cholesterol-Modifying Pharmacotherapy: An Illustrative Example Focusing on the Primary Prevention of Coronary Heart Disease in Canada

Author： Morris S.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.16, Iss.2, 1999-08, pp. : 193-205

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Treating Low HDL-Cholesterol in the Primary Prevention of Coronary Heart Disease

By Hay Joel W.  

PharmacoEconomics, Vol. 23, Iss. 2, 2005-01 ,pp. : 133-141

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis for Statin Therapies in the Primary Prevention of Coronary Heart Disease in Italy

By Berto P.  

Clinical Drug Investigation, Vol. 20, Iss. 2, 2000-08 ,pp. : 109-121

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Treatments to Reduce Cholesterol Levels, Blood Pressure and Smoking for the Prevention of Coronary Heart Disease: Evaluative Study Carried Out in Spain

By Plans-Rubió P.  

PharmacoEconomics, Vol. 13, Iss. 5, 1998-05 ,pp. : 623-643

Adis International

Access to resources Recommend Favorite

Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness

By Ho Wai Khoon   Hankey Graeme J   Eikelboom John W  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 3, 2004-03 ,pp. : 493-503

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults

By Brown A.D.  

PharmacoEconomics, Vol. 14, Iss. 1, 1998-07 ,pp. : 27-48

Adis International

Access to resources Recommend Favorite